Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

OKYO Stock Latest News

RatingsAnalyst Reaffirms Buy on OKYO as Urcosimod Enters Pivotal Phase 3; $5 Price Target Maintained4w agoOKYO

Company AnnouncementsOKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain4w ago6K OKYO
The FlyOkyo Pharma announces first patients enrolled in NEPTUNE trial4w agoOKYO
Company AnnouncementsOKYO Pharma to Highlight Neuropathic Corneal Pain Program at Key Ophthalmic Conferences1M ago6K OKYO
Company AnnouncementsOKYO Pharma to Showcase Urcosimod at Key European Ophthalmology Forums1M ago6K OKYO

OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference

Company AnnouncementsOKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference1M ago6K OKYO

The FlyOkyo Pharma management to meet virtually with Piper Sandler2M agoOKYO

Company AnnouncementsOKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial3M ago6K OKYO

The FlyOkyo Pharma CSO Raj Patil purchases 3,363 shares at $1.493M agoOKYO
Company AnnouncementsOKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 20263M ago6K OKYO
Company AnnouncementsOKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial3M ago6K OKYO
The FlyOkyo Pharma director John Brancaccio acquires 5,000 shares at $1.383M agoOKYO

Okyo Pharma CEO Robert Dempsey purchases 15,000 shares at $1.54

The FlyOkyo Pharma CEO Robert Dempsey purchases 15,000 shares at $1.543M agoOKYO

Company AnnouncementsOKYO Pharma CEO Boosts Stake With Nasdaq Share Purchase3M ago6K OKYO

Company AnnouncementsOKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial3M ago6K OKYO

The FlyOkyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share3M agoOKYO
Company AnnouncementsOKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial3M ago6K OKYO
The FlyOkyo Pharma says CDO Gary Jacob purchases 3,500 shares for $1.40 per share3M agoOKYO
The FlyOkyo Pharma CMO Flavio Mantelli purchases 20,000 shares at $1.403M agoOKYO

OKYO Pharma CMO Boosts Stake Ahead of Planned Global Phase 3 Trial

Company AnnouncementsOKYO Pharma CMO Boosts Stake Ahead of Planned Global Phase 3 Trial3M ago6K OKYO

Company AnnouncementsOKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial3M ago6K OKYO

Company AnnouncementsOKYO Pharma Chairman Boosts Stake Ahead of Phase 3 Neuropathic Corneal Pain Trial3M ago6K OKYO